A5010415339- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Eosinophilic Disorders and Syndromes
- Viral Infectious Diseases and Gene Expression in Insects
- Particle Accelerators and Free-Electron Lasers
- Peptidase Inhibition and Analysis
- Blood disorders and treatments
- Acute Lymphoblastic Leukemia research
- Particle physics theoretical and experimental studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Hematopoietic Stem Cell Transplantation
- Superconducting Materials and Applications
- Biosimilars and Bioanalytical Methods
- Pneumonia and Respiratory Infections
Universitätsklinikum Würzburg
2019-2024
University of Würzburg
2016-2024
Blinatumomab can induce a complete haematological remission in patients 46.6% with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting survival benefit when compared chemotherapy. Only bone marrow blast counts before therapy have shown weak prediction of response. Here we investigated the role regulatory T cells (Tregs), measured by CD4/CD25/FOXP3 expression, predicting outcome immunotherapy CD19-directed bispecific T-cell engager construct blinatumomab....
Immunotherapy of B-cell malignancies with bispecific antibodies is an emerging treatment option. However, not all patients benefit from these therapies, presumably due to pretreatment regimens. Therefore, we determined the effect different lines on activity T cells and their responsiveness AFM11. AFM11 a tetravalent, CD19/CD3 immunoengager based Affimed’s ROCK platform, currently being investigated in phase I clinical trials for non-Hodgkin lymphoma acute lymphoblastic leukemia. treated...
Summary Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, (iii) >day+30 after therapy. evaluated laboratory data performed flow cytometry to determine the (CAR) subsets. Baseline...
Abstract Patients with multiple myeloma (MM) are at high risk for infections, including opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP). We conducted a retrospective analysis of patients MM developing PJP over 6-year period between January 2016 and December 2021 the University Hospital Würzburg by screening cases microbiologically documented PJP. A total 201 positive results P. in respiratory specimens were retrospectively retrieved through our microbiology database....
Background: Burkitt leukemia and lymphoma can be cured in majority of patients with intensified immune chemotherapy protocols. For who replapse or are even refractory (r/r) the prognosis is dismal. Blinatumomab (Blin) a CD19 targeted bispecifc T‐cell engager, which induces as single agent complete remissions r/r B‐precursor ALL at target dose 28 mg/d. NHL, Blin 112 mg/d, reach after 2 weeks for therapy. Nevertheless, despite slow ramp does grade III/IV neurotoxicity (NT) observed 25%...
The combination of venetoclax with hypomethylating agents is currently the standard care for elderly patients acute myeloid leukemia (AML) ineligible intensive chemotherapy. Despite its favorable efficacy, clinical use often associated post-remission cytopenia, frequently necessitating treatment delays and dose modifications. This study aims to evaluate efficacy safety shortened durations. A multicenter analysis was conducted involving 20 adult AML receiving (7 or 14 days 9 11 patients,...
Abstract CD19 CAR T cells and CD20 targeting cell engaging bispecific antibodies have been approved in B-cell Non-Hodgkin lymphoma lately, heralding a new clinical setting where patients are treated with both approaches, sequentially. The aim of our study was to investigate the selective pressure directed therapy on clonal architecture lymphoma. Using broad analytical pipeline, we identified truncating mutations gene encoding conferring antigen loss 80% relapsing from bispecs. Pronounced...
High-risk (HR) multiple myeloma (MM) patients still have a very poor prognosis. However, the definition of HR MM remains controversial. Currently, FISH is most commonly used method for risk stratification in MM. According to Second Revised International Staging System (R2-ISS), cytogenetics defined as presence at least one following: del(17p), t(4;14), and 1q CNA. In recent years, gene expression profiling (GEP) approaches, e.g. SKY92, been developed detection patients. R2-ISS era, however,...
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: The definition of high-risk (HR) multiple myeloma (MM) is controversial. Currently, FISH the most commonly used tool for risk stratification in MM. According to R2-ISS, HR cytogenetics defined as presence del(17p), t(4;14), and/or 1q CNA. On hand, SKY92 gene expression profiling has been developed detection MM clinical trials. However, data on combining with according R2-ISS still missing. Aims: aim this study was...